Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
67
GRFS Quote, Financials, Valuation and Earnings
Last price:
$9.09
Seasonality move
:
0.62%
Day range:
$8.94 - $9.11
52-week range:
$6.19 - $11.14
Dividend yield:
1.91%
P/E ratio:
14.82x
P/S ratio:
0.74x
P/B ratio:
2.69x
Volume:
247.4K
Avg. volume:
521.7K
1-year change:
15.92%
Market cap:
$6.2B
Revenue:
$7.8B
EPS (TTM):
$0.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GRFS
Grifols SA
|
$2.2B | $0.28 | 5.84% | 166.03% | $11.10 |
|
ASND
Ascendis Pharma A/S
|
$245M | -$0.18 | 55.74% | -75.47% | $262.82 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$5M | -$0.00 | -100% | -88.57% | $7.20 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GRFS
Grifols SA
|
$9.10 | $11.10 | $6.2B | 14.82x | $0.17 | 1.91% | 0.74x |
|
ASND
Ascendis Pharma A/S
|
$208.98 | $262.82 | $12.8B | -- | $0.00 | 0% | 17.48x |
|
AUTL
Autolus Therapeutics Plc
|
$1.67 | $9.52 | $444.5M | -- | $0.00 | 0% | 8.67x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.63 | $17.94 | $2.2M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$2.31 | $7.20 | $367.3M | -- | $0.00 | 0% | 721.31x |
|
NCNA
NuCana Plc
|
$3.31 | $104.00 | $13.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GRFS
Grifols SA
|
65.17% | 1.358 | 119.05% | 0.80x |
|
ASND
Ascendis Pharma A/S
|
127.22% | -0.522 | 7.87% | 0.68x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GRFS
Grifols SA
|
$857.4M | $411M | 2.61% | 5.73% | 18.85% | $250.8M |
|
ASND
Ascendis Pharma A/S
|
$219.4M | $12.9M | -34.4% | -880.05% | 5.15% | $1.3M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Grifols SA vs. Competitors
-
Which has Higher Returns GRFS or ASND?
Ascendis Pharma A/S has a net margin of 7.69% compared to Grifols SA's net margin of -28.55%. Grifols SA's return on equity of 5.73% beat Ascendis Pharma A/S's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital GRFSGrifols SA39.33% $0.22 $20.3B ASNDAscendis Pharma A/S87.87% -$1.17 $751.5M -
What do Analysts Say About GRFS or ASND?
Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 21.98%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $262.82 which suggests that it could grow by 25.76%. Given that Ascendis Pharma A/S has higher upside potential than Grifols SA, analysts believe Ascendis Pharma A/S is more attractive than Grifols SA.
Company Buy Ratings Hold Ratings Sell Ratings GRFSGrifols SA1 1 0 ASNDAscendis Pharma A/S13 0 0 -
Is GRFS or ASND More Risky?
Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.182%.
-
Which is a Better Dividend Stock GRFS or ASND?
Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.91%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRFS or ASND?
Grifols SA quarterly revenues are $2.2B, which are larger than Ascendis Pharma A/S quarterly revenues of $249.6M. Grifols SA's net income of $167.6M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, Grifols SA's price-to-earnings ratio is 14.82x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.74x versus 17.48x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRFSGrifols SA0.74x 14.82x $2.2B $167.6M ASNDAscendis Pharma A/S17.48x -- $249.6M -$71.3M
-
Which has Higher Returns GRFS or AUTL?
Autolus Therapeutics Plc has a net margin of 7.69% compared to Grifols SA's net margin of -373.3%. Grifols SA's return on equity of 5.73% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital GRFSGrifols SA39.33% $0.22 $20.3B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About GRFS or AUTL?
Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 21.98%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 470.19%. Given that Autolus Therapeutics Plc has higher upside potential than Grifols SA, analysts believe Autolus Therapeutics Plc is more attractive than Grifols SA.
Company Buy Ratings Hold Ratings Sell Ratings GRFSGrifols SA1 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is GRFS or AUTL More Risky?
Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock GRFS or AUTL?
Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.91%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRFS or AUTL?
Grifols SA quarterly revenues are $2.2B, which are larger than Autolus Therapeutics Plc quarterly revenues of $21.1M. Grifols SA's net income of $167.6M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Grifols SA's price-to-earnings ratio is 14.82x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.74x versus 8.67x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRFSGrifols SA0.74x 14.82x $2.2B $167.6M AUTLAutolus Therapeutics Plc8.67x -- $21.1M -$78.6M
-
Which has Higher Returns GRFS or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 7.69% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 5.73% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital GRFSGrifols SA39.33% $0.22 $20.3B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About GRFS or BDRX?
Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 21.98%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 6662.41%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Grifols SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Grifols SA.
Company Buy Ratings Hold Ratings Sell Ratings GRFSGrifols SA1 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is GRFS or BDRX More Risky?
Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock GRFS or BDRX?
Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.91%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRFS or BDRX?
Grifols SA quarterly revenues are $2.2B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Grifols SA's net income of $167.6M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Grifols SA's price-to-earnings ratio is 14.82x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.74x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRFSGrifols SA0.74x 14.82x $2.2B $167.6M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns GRFS or MREO?
Mereo BioPharma Group Plc has a net margin of 7.69% compared to Grifols SA's net margin of -2923.31%. Grifols SA's return on equity of 5.73% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital GRFSGrifols SA39.33% $0.22 $20.3B MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About GRFS or MREO?
Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 21.98%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $7.20 which suggests that it could grow by 211.76%. Given that Mereo BioPharma Group Plc has higher upside potential than Grifols SA, analysts believe Mereo BioPharma Group Plc is more attractive than Grifols SA.
Company Buy Ratings Hold Ratings Sell Ratings GRFSGrifols SA1 1 0 MREOMereo BioPharma Group Plc6 0 0 -
Is GRFS or MREO More Risky?
Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.425%.
-
Which is a Better Dividend Stock GRFS or MREO?
Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.91%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRFS or MREO?
Grifols SA quarterly revenues are $2.2B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Grifols SA's net income of $167.6M is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, Grifols SA's price-to-earnings ratio is 14.82x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.74x versus 721.31x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRFSGrifols SA0.74x 14.82x $2.2B $167.6M MREOMereo BioPharma Group Plc721.31x -- -- -$7M
-
Which has Higher Returns GRFS or NCNA?
NuCana Plc has a net margin of 7.69% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 5.73% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital GRFSGrifols SA39.33% $0.22 $20.3B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About GRFS or NCNA?
Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 21.98%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 628298.79%. Given that NuCana Plc has higher upside potential than Grifols SA, analysts believe NuCana Plc is more attractive than Grifols SA.
Company Buy Ratings Hold Ratings Sell Ratings GRFSGrifols SA1 1 0 NCNANuCana Plc0 1 0 -
Is GRFS or NCNA More Risky?
Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock GRFS or NCNA?
Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.91%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRFS or NCNA?
Grifols SA quarterly revenues are $2.2B, which are larger than NuCana Plc quarterly revenues of --. Grifols SA's net income of $167.6M is higher than NuCana Plc's net income of -$378.9K. Notably, Grifols SA's price-to-earnings ratio is 14.82x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.74x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRFSGrifols SA0.74x 14.82x $2.2B $167.6M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
